CClinicalTrials.gg
Enrolling by invitationNCT07412743PEERUpdated May 1, 2026

Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers

An interventional study of Mailers and Provider Materials in School Health Services, sponsored by Kaiser Permanente. Enrolling by invitation at 1 site in United States. Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
9 Years to 18 Years
Sex
All
01

Study summary

School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are educated about the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States.

02

Conditions studied

  • School Health Services
03

In context

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 9-18
  • New or established patients
  • Flagged if due for an HPV vaccine

Exclusion criteria

Exclusion Criteria:

- None

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
4,000 participants (estimated)

Study arms

  • No intervention
    Control time (pre-implementation)

    All participating SBHCs offer routine HPV vaccination recommendations as part of clinical care and SBHC staff will continue to follow standard procedures to deliver these services. Further, all SBHCs have existing relationships with the affiliated schools, so the delivery of these healthcare services in the context of schools will not deviate from usual care.

  • Experimental
    Intervention (post-implementation)

    Intervention components (mailers, provider materials, and peer-to-peer educational sessions) will be administered during the intervention portion of each cluster.

    Behavioral: Mailers · Behavioral: Provider Materials · Behavioral: Peer-to-Peer Educational Sessions

Interventions

  • BehavioralMailers

    Letter and fact sheet (infographic) mailed to caregivers of 9-14 year-olds and to teens 15-18, with optional phone call for "confidential patients" aged 15-18.

  • BehavioralProvider Materials

    Clinic team/staff training based on qualitative interviews, recommended strategies and evidence-based interventions. Training materials include FAQs and Smart phrases. FAQs and informational sheets containing the same content as the mailers distributed in clinic to teen SBHC patients and their caregivers.

  • BehavioralPeer-to-Peer Educational Sessions

    Educational sessions delivered in schools by OSBHA interns. Session content includes SBHC information and HPV awareness.

06

What researchers measure

Primary outcomes

  1. Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination)

    Vaccination among eligible clinic patients, and time to vaccination

    Time frame: 6 and 12 months

Secondary outcomes

  1. Rates of new patients to the clinic (n of new patients/n of established patients)

    New patients seen (vs. prior seen pts.) - New patient characteristics (age, rural)

    Time frame: 6 and 12 months

  2. Rate of use of other SBHC services (primary care visits, wellness assessments) (n of patients with primary care visits/n of new and established patients)

    Use of other SBHC services and visits among eligible clinic patients

    Time frame: 6 and 12 months

  3. Rate of vaccination for other adolescent vaccinations (COVID-19, flu, Meningitis, or uptick of other vax's (TDAP, MMR, etc.)) (n of patients with additional vaccination among new and eligible clinic patients)

    Vaccination among eligible clinic patients, and time to vaccination

    Time frame: 6 and 12 months

07

Study locations

1 site
  • Kaiser Permanente Center for Health Research
    Portland, Oregon 97227, United States
08

References and documents

Individual participant data

Plan to share: No — Deidentified data and accompanying data dictionaries will be stored for future sharing as anonymized data sets in a data repository per NIH data sharing requirements.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07412743
Lead sponsor
Kaiser Permanente
Collaborators
National Institute on Minority Health and Health Disparities (NIMHD)
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Jan 12, 2026
Primary completion
Aug 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
May 1, 2026

Study contacts

Amanda Petrik, PhD
principal investigator · Kaiser Permanente

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion